PNOC 008: A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High Grade Glioma (Excluding Diffuse Intrinsic Pontine Glioma)

The main purpose of this study is to find out if personalized cancer medicine can treat or stop high-grade glioma (HGG) from getting worse.

Eligibility

• Newly diagnosed HGG (including midline HGG but excluding DIPG), who undergo tissue collection as part of standard of care.
• Enrollment within 3 weeks of the start of radiation therapy.
• Start of radiation therapy within 6 weeks from initial tissue diagnosis.
• Adequate tissue for molecular profiling.

Procedures

Part 1
During the first part of this study, your tumor tissue and blood samples will be tested to gather information about your cancer. The tumor tissue is collected from the surgery you had as part of your regular care.

These test results will be returned to you and your doctor within a written report. The results of this testing will be reviewed by a specialized Tumor Board.

The Tumor Board is a group of doctors with different specialties who meet and discuss your tests results, medical history, and available treatment options to determine a recommended treatment for you.

You will not receive the recommended treatments until you have completed your standard of care radiation therapy.

Part 2
The second part involves treatment with study drug(s) the Tumor Board selects for you. Your study doctor will discuss the treatment plan with you, including the side effects of the drug(s) as well as follow up tests that might be needed.

In choosing the drug(s) for treatment, close attention will be paid to safety, how the drug(s) work, and if more than one drug is used how the drug(s) might interact with each other.

Contact

If you or your loved one are interested, please contact Jennifer King at:

• jennifer.king@neurosurgery.ufl.edu
• (352) 294-8374